The market for direct-to-consumer DNA tests has become saturated, so what will 23andMe do now?
As Thomas Germain reports in Gizmodo, the plan may involve selling more customer data to the pharmaceutical industry and a subscription model promising more tests for rare genomic conditions and risk factors for more common conditons.